Analyst Barrington raised ICF International's price target to $110, suggesting a 24.45% upside from $88.39. The company expects 3% revenue growth and 5% non-GAAP EPS growth in 2026, fueled by energy, AI, and federal modernization efforts. Q2 2026 earnings beat estimates by 10.1%, supported by strong commercial and international government revenue growth. With a $9.3 billion pipeline and a book-to-bill ratio above 1, ICF's future business outlook is solid.
HSBC has upgraded YPF's rating to Buy following strong Q2 2026 results, including a 41.7% revenue increase to $6.57 billion and earnings per share of $3.07, surpassing estimates. YPF raised its 2026 adjusted EBITDA guidance to $8 billion and aims for...
Vivos Therapeutics reported Q2 2026 earnings per share of -$0.31, beating analyst expectations of -$0.42, but its revenue of $5.15 million fell short of the $5.63 million estimate. The company, focused on sleep apnea treatments, sees growing patient ...
Several leading stocks, including SoundThinking, TSS, and ADI Global Distribution, dropped significantly due to factors like lowered revenue forecasts and disappointing quarterly results. SoundThinking fell over 25% after cutting its revenue outlook ...
Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the pric...
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...
